elevet+ Maxalac L.C. Intramammary Antibiotic

দেশ: অস্ট্রেলিয়া

ভাষা: ইংরেজি

সূত্র: APVMA (Australian Pesticides and Veterinary Medicines Authority)

সক্রিয় উপাদান:

CEFUROXIME SODIUM

থেকে পাওয়া:

AVET HEALTH LIMITED

INN (আন্তর্জাতিক নাম):

cefuroxime sodium(92.2g/kg)

ফার্মাসিউটিকাল ফর্ম:

MISC. INTRA MAMMARY

রচনা:

CEFUROXIME SODIUM ANTIBIOTIC Active 92.2 g/kg

প্যাকেজ ইউনিট:

20x3g; 3g syringe

শ্রেণী:

VM - Veterinary Medicine

থেরাপিউটিক গ্রুপ:

DAIRY CATTLE | BOVINE | BREEDERS | CALVES | DAIRY COW | GROWERS | LACTATING COW | MILKING COW

থেরাপিউটিক এলাকা:

ANTIBIOTIC & RELATED

থেরাপিউটিক ইঙ্গিত:

CITROBACTER FREUNDII SPP. | CORYNEBACTERIA | ENTEROBACTER SPP. | ESCHERICHIA COLI (E. COLI) | KLEBSIELLA SPP. | MASTITIS | MICROCOCCUS SPP. | STAPHYLOCOCCUS AUREUS | STAPHYLOCOCCUS SPP. | STREPTOCOCCUS AGALACTIAE | STREPTOCOCCUS DYSGALACTIAE | STREPTOCOCCUS UBERIS | INCLUDING B-LACTAMASE PRODUCIN | STAPHYLOCOCCOSIS | SUBCLINICAL MASTITIS

পণ্য সারাংশ:

Poison schedule: 4; Withholding period: MEAT: DO NOT USE less than 7 days before slaughter for human consumption. MILK: Milk taken from cows within 72 hours (6 milkings) following last treatment MUST NOT BE USED for human consumption or su pplied for processing. This milk should not be fed to bobby calves. ESI: This product does not have an ESI establishe d. For advice on the ESI contact Jurox P ty Ltd on 1800 023 312 before using this product.; Host/pest details: DAIRY CATTLE: [CITROBACTER FREUNDII SPP., CORYNEBACTERIA, ENTEROBACTER SPP., ESCHERICHIA COLI (E. COLI), KLEBSIELLA SPP., MASTITIS, MICROCOCCUS SPP., STAPHYLOCOCCUS AUREUS, STAPHYLOCOCCUS SPP., STREPTOCOCCUS AGALACTIAE, STREPTOCOCCUS DYSGALACTIAE, STREPTOCOCCUS UBERIS]; Poison schedule: 4; Withholding period: WHP: MEAT: DO NOT USE less than 7 days before slaughter for human consumption . MILK: Milk taken from cows within 72 hours (6 milkings) following last trea tment MUST NOT BE USED for human consum ption or supplied for processing. This milk should not be fed to bobby calves. ESI: This product does not have an ESI established. For advice on the ESI co ntact Jurox Pty Ltd on 1800 023 312 be fore using this product.; Host/pest details: DAIRY CATTLE: [CITROBACTER FREUNDII SPP., CORYNEBACTERIA, ENTEROBACTER SPP., ESCHERICHIA COLI (E. COLI), KLEBSIELLA SPP., MASTITIS, MICROCOCCUS SPP., STAPHYLOCOCCUS AUREUS, STAPHYLOCOCCUS SPP., STREPTOCOCCUS AGALACTIAE, STREPTOCOCCUS DYSGALACTIAE, STREPTOCOCCUS UBERIS]; Poison schedule: 4; Withholding period: ; Host/pest details: DAIRY CATTLE: [CITROBACTER FREUNDII SPP., CORYNEBACTERIA, ENTEROBACTER SPP., ESCHERICHIA COLI (E. COLI), KLEBSIELLA SPP., MASTITIS, MICROCOCCUS SPP., STAPHYLOCOCCUS AUREUS, STAPHYLOCOCCUS SPP., STREPTOCOCCUS AGALACTIAE, STREPTOCOCCUS DYSGALACTIAE, STREPTOCOCCUS UBERIS]; For broad spectrum control of mastitis causing bacteria (including penicillin resistant strains) in lactating dairy cattle.Milk for human consumption must not be taken from a cow during treatment. Milk taken from cows within 72 hours (6 milkings) following last treatment must NOT be fed to bobby calves.

অনুমোদন অবস্থা:

Registered

অনুমোদন তারিখ:

2023-07-01

তথ্য লিফলেট

elevet+
MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC
59528/139099
Product Name:
APVMA Approval No
:
Label Name:
elevet+
MAXALAC L.C. INTRAMAMMARY ANTIBIOTIC
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
92.2 g/kg CEFUROXIME SODIUM
(250 mg/3 g syringe CEFUROXIME)
Claims:
For broad spectrum control of mastitis-causing bacteria (including
penicillin resistant
strains) in lactating dairy cattle.
Net Contents:
20 x 3 g syringe
3 g syringe
Directions for Use:
Restraints:
Milk for human consumption must not be taken from a cow during
treatment.
Contraindications:
Precautions:
Side Effects:
Dosage and
Administration:
Use elevet+ Maxalac L.C. Intramammary Antibiotic as directed by your
veterinary surgeon
as part of a mastitis control program.
Wear gloves when infusing the treatment.
Before infusion the teat should be thoroughly cleaned and disinfected.
The contents of one syringe should be infused into the teat canal of
each infected quarter
every 12 hours, after each of three successive milkings. RLP APPROVED
Administration
1. After milking is complete, thoroughly clean and disinfect the end
of the teat (e.g. with
cotton wool soaked in alcohol).
2. Hold the barrel of the syringe firmly in one hand and gently twist
and pull the protective
cap in a straight line to remove it, taking care not to contaminate
the nozzle.
3. Insert the nozzle fully into the teat canal and apply steady
pressure on the syringe
plunger until the full dose has been delivered. Holding the end of the
teat with one
hand, gently massage upwards with the other to aid dispersion of the
antibiotic into the
quarter.
4. After infusion it is advisable to dip the teats in an antiseptic
preparation specifically
designed for this purpose.
Any variation by the prescribing veterinarian to the approved dose,
frequency, duration,
route, disease or target species may require extending the approved
withholding period.
General Directions:
Indications
elevet+ Maxalac L.C. Intramammary Antibiotic is

পণ্য বৈশিষ্ট্য

MAXALAC LC INTRAMAMMARY
Page 1 of 5
continued
ISSUED:
3 OCTOBER 2012
SAFETY DATA SHEET
SECTION 1: IDENTIFICATION OF CHEMICAL PRODUCT AND COMPANY
PRODUCT NAME:
MAXALAC LC INTRAMAMMARY ANTIBIOTIC
PRODUCT CODE:
503205 (20 x 3g syringes)
RECOMMENDED USE:
An intramammary infusion to treat mastitis in lactating cows.
COMPANY IDENTIFICATION:
Jurox Pty Limited
ADDRESS:
85 Gardiner Street
Rutherford NSW 2320
Australia
CUSTOMER CENTRE:
1800 023 312
NATIONAL POISONS INFORMATION CENTRE:
131126 (Australia-wide)
EMERGENCY TELEPHONE NUMBER:
1800 023 312 (9a.m. – 5p.m.)
SECTION 2: HAZARDS IDENTIFICATION
GHS HAZARD CLASSIFICATIONS:
RESPIRATORY SENSITIZER CATEGORY 1
SKIN SENSITIZER CATEGORY 1
GHS PICTOGRAMS:
HEALTH HAZARD
EXCLAMATION MARK
SIGNAL WORD*:
DANGER
HAZARD STATEMENTS*:
H317
May cause an allergic skin reaction.
H334
May cause allergy or asthma symptoms or breathing difficulties if
inhaled.
PRECAUTIONARY STATEMENTS*:
PREVENTION
P261
Avoid breathing vapours.
P272
Contaminated work clothing should not be allowed out of the workplace.
P280
Wear protective gloves/protective clothing/eye protection/face
protection.
P285
In case of inadequate ventilation wear respiratory protection.
RESPONSE
P302+P352
IF ON SKIN: Wash with plenty of soap and water.
P304+P341
IF INHALED: If breathing is difficult, remove victim to fresh air and
keep at rest in a position comfortable for breathing.
P333+P313
If skin irritation or rash occurs: Get medical advice.
P342+P311
If experiencing respiratory symptoms: Call a POISON CENTER or
doctor.
P363
Wash contaminated clothing before reuse.
DISPOSAL
P501
Dispose of contents / container in accordance with local / national
regulations.
* N.B.: These statements are determined by Work Health and Safety
regulations and may not reflect Signal Headings and
First Aid and Safety statements on product labelling, which are
determined by a competent authority during assessment
for registration.
MAXALAC LC INTRAMAMMARY
Page 2 of 5
continued
SECTION 3: COMPOSITION / INFORMATION ON INGREDIENTS
INGREDIENT
CAS NO.
CO

নিরাপত্তা তথ্য শীট

WWW.JUROX.COM.AU
Customer Service 1800 023 312
® Registered Trademark of Jurox Pty Limited
TECHNICAL NOTES
ACTIVE CONSTITUENT
Each syringe contains 250 mg cefuroxime (as cefuroxime sodium)
ACTIONS
MAXALAC® L.C. is indicated for the treatment of clinical mastitis in
milking cows. It is an intramammary infusion containing cefuroxime
in a quick-release oily base. The base disperses readily in milk and
allows rapid distribution of high levels of antibiotic in both milk
and
tissues of treated quarters.
Cefuroxime sodium is a second generation, semi-synthetic cephalosporin
antibiotic which is resistant to degradation by beta-
lactamase enzymes produced by both Gram-positive and Gram-negative
mastitis pathogens.
INDICATIONS
For the treatment of clinical mastitis caused by the following
pathogens: _Staphylococcus spp., Staphylococcus aureus_, including
penicillin resistant spp.,_ Streptococcus agalacatiae, Streptococcus
dysgalactiae, Streptococcus uberis, Escherichia coli, Corynebacterium
_spp.
(including _Arcanobacterium pyogenes_). The antibiotic, cefuroxime, is
also active against other organisms recovered from the bovine
udder including _Klebsiella _spp.,_ Citrobacter _spp.,_ Enterobacter
_spp_. and Micrococcus _spp.
MAXALAC® L.C. is therefore suitable for the treatment of clinical
mastitis caused by all the major mastitis pathogens.
RESTRAINTS
Milk for human consumption must not be taken from a cow during
treatment.
PRECAUTIONS
Any variation by the prescribing veterinarian to the approved dose,
frequency, duration, route, disease or target species may require
extending the approved withholding period.
Wear sanitised rubber gloves when applying.
MAXALAC
®
L.C.
Intramammary Antibiotic
WWW.JUROX.COM.AU
Customer Service 1800 023 312
® Registered Trademark of Jurox Pty Limited
TECHNICAL NOTES
WITHHOLDING PERIODS
MILK: Milk taken from cows within 72 hours (6 milkings) following last
treatment MUST NOT BE USED for human consumption or
supplied for processing. This milk should not be fed to bobby calves.
MEAT: DO NOT U